Quarterly ResultAug 13, 2026, 04:25 PM
Moleculin Biotech Q2 Net Loss $7.6M; Going Concern Doubt
AI Summary
Moleculin Biotech reported a net loss of $7.6 million for Q2 2026 and $20.5 million for the six months ended June 30, 2026. The company's cash and cash equivalents decreased to $7.3 million, which management believes is insufficient to fund operations for the next year, raising substantial doubt about its ability to continue as a going concern. The company continues to focus on its Annamycin Phase 2/3 trial for AML and is planning additional clinical trials for other drug candidates.
Key Highlights
- Q2 2026 net loss was $7.6 million, compared to $17.8 million in Q2 2025.
- Cash and cash equivalents stood at $7.3 million as of June 30, 2026.
- Accumulated deficit reached $226.5 million as of June 30, 2026.
- Management expressed substantial doubt about the company's ability to continue as a going concern.
- Net cash used in operating activities increased to $12.8 million for six months 2026.
- Research and development expenses rose to $10.8 million for six months 2026.
- Company closed its Australian subsidiary to reduce corporate overhead costs.
- Implemented a 1-for-25 reverse stock split on December 1, 2025.
Price Impact
More from MBRX